Pharmacological treatment of non-Alzheimer dementias.
OBJECTIVE
One hundred years after the first description by Alois Alzheimer and with the advent of first pharmacological treatments, most researchers concentrate on Alzheimer's disease. Millions of patients, however, suffer from other dementias and search for help beyond diagnosis.


RESULTS
New clinical data concerning the treatment of non-Alzheimer dementias mainly relate to the clinical use of antidementiva that is already approved for the treatment of Alzheimer's disease. Few studies test new pharmacological paradigmata. For some forms like vascular dementias, the possibility of prevention is the most valuable approach that should be enforced more aggressively. For other savaging dementias new unconventional treatment trials should be encouraged.


CONCLUSIONS
Research for non-Alzheimer dementias lags behind those for the Alzheimer field. For many patients, we still have nothing but words. At the same time, probably with regard to cost constraints, some acteurs like health insurances and legislators are inclined to nurture therapeutic nihilism and cultivate ethical qualms and demurs instead of supporting clinical trials or at least not blocking them with bureaucratic hand-cuffs, whereas pharmaceutical companies contemplate naturally over questions like return of investment. The clinical researchers should fight this fatigue and look for ways out of this quagmire for our patients.
Arlt
Sönke
S
Department of Psychiatry and Psychotherapy, University Hospital Hamburg-Eppendorf (UKE), Hamburg, Germany.
Jahn
Holger
H
D002986:Clinical Trials as Topic; D003704:Dementia / Q000188:drug therapy* / Q000517:prevention & control; D006801:Humans; D011619:Psychotropic Drugs / Q000627:therapeutic use*
D011619:Psychotropic Drugs